Katrin Ounap

Prof. Katrin Ounap

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2018 in Nature Reviews Endocrinology
Verified
Journal Article
Open access
PDF file
FBFrédéric Brioude
Frédéric Brioude
JKJennifer M. Kalish
Jennifer M. Kalish
AMAlessandro Mussa
Alessandro Mussa
AFAlison C. Foster
Alison C. Foster
JBJet Bliek
Jet Bliek
EMEamonn R. Maher
Eamonn R. Maher
Beckwith–Wiedemann syndrome (BWS), a human genomic imprinting disorder, is characterized by phenotypic variability that might include overgrowth, macroglossia, abdominal wall defects, neonatal hypoglycaemia, lateralized overgrowth and predisposition to embryonal tumours. Delineation of the molecular defects within the imprinted 11p15.5 region can predict familial recurrence risks and the risk (and type) of embryonal tumour. Despite recent advances in knowledge, there is marked heterogeneity in clinical diagnostic criteria and care. As detailed in this Consensus Statement, an international consensus group agreed upon 72 recommendations for the clinical and molecular diagnosis and management of BWS, including comprehensive protocols for the molecular investigation, care and treatment of patients from the prenatal period to adulthood. The consensus recommendations apply to patients with Beckwith–Wiedemann spectrum (BWSp), covering classical BWS without a molecular diagnosis and BWS-related phenotypes with an 11p15.5 molecular anomaly. Although the consensus group recommends a tumour surveillance programme targeted by molecular subgroups, surveillance might differ according to the local health-care system (for example, in the United States), and the results of targeted and universal surveillance should be evaluated prospectively. International collaboration, including a prospective audit of the results of implementing these consensus recommendations, is required to expand the evidence base for the design of optimum care pathways.

4 February 2010 in Nature
Verified
Journal Article
Open access
PDF file
RWRobin Walters
Robin Walters
SJS. Jacquemont
S. Jacquemont
AVA. Valsesia
A. Valsesia
ASA. J. de Smith
A. J. de Smith
DMD. Martinet
D. Martinet
JBJ. S. Beckmann
J. S. Beckmann
Obesity is a highly heritable disorder but the genetic associations reported to date account for only a small percentage of the inherited variation in body mass index. Two groups report deletions on chromosome16p11.2 that may explain part of the 'missing heritability' in terms of 'high-penetrance' mutations that are rare but when present are very often associated with severe obesity. This is in contrast to more common gene defects that are less closely associated with clinical symptoms. Bochukova et al. identified rare recurrent copy number variants in 300 patients with severe early-onset obesity, caused by deletions involving several genes including SH2B1, known to be involved in leptin and insulin signalling. Many of the patients also suffered neurodevelopmental disorders. Walters et al. identified deletions of at least 593 kilobases on chromosome 16p11.2 in 31 patients with a previously unrecognized type of extreme obesity. The strategy they used to identify the lesion — using small well-phenotyped cohorts of extreme phenotypes with targeted follow-up in genome-wide association studies and population cohorts — shows promise as a means of identifying 'missing heritability' in complex metabolic diseases more generally. Recently, numerous single nucleotide polymorphisms have been identified as being associated with obesity, but these loci together account for only a small fraction of the known heritable component. Here, an association is reported between rare deletions of at least 593 kilobases at 16p11.2 and a highly penetrant form of obesity. The strategy used of combining study of extreme phenotypes with targeted follow-up is promising for identifying missing heritability in obesity. Obesity has become a major worldwide challenge to public health, owing to an interaction between the Western ‘obesogenic’ environment and a strong genetic contribution1. Recent extensive genome-wide association studies (GWASs) have identified numerous single nucleotide polymorphisms associated with obesity, but these loci together account for only a small fraction of the known heritable component1. Thus, the ‘common disease, common variant’ hypothesis is increasingly coming under challenge2. Here we report a highly penetrant form of obesity, initially observed in 31 subjects who were heterozygous for deletions of at least 593 kilobases at 16p11.2 and whose ascertainment included cognitive deficits. Nineteen similar deletions were identified from GWAS data in 16,053 individuals from eight European cohorts. These deletions were absent from healthy non-obese controls and accounted for 0.7% of our morbid obesity cases (body mass index (BMI) ≥ 40 kg m-2 or BMI standard deviation score ≥ 4; P = 6.4 × 10-8, odds ratio 43.0), demonstrating the potential importance in common disease of rare variants with strong effects. This highlights a promising strategy for identifying missing heritability in obesity and other complex traits: cohorts with extreme phenotypes are likely to be enriched for rare variants, thereby improving power for their discovery. Subsequent analysis of the loci so identified may well reveal additional rare variants that further contribute to the missing heritability, as recently reported for SIM1 (ref. 3). The most productive approach may therefore be to combine the ‘power of the extreme’4 in small, well-phenotyped cohorts, with targeted follow-up in case-control and population cohorts.

1 November 2017 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
FHFadi F. Hamdan
Fadi F. Hamdan
CMCandace T. Myers
Candace T. Myers
PCPatrick Cossette
Patrick Cossette
PLPhilippe Lemay
Philippe Lemay
DSDan Spiegelman
Dan Spiegelman
JMJacques L. Michaud
Jacques L. Michaud

1 September 2011 in The Lancet Neurology
Verified
Journal Article
Closed access
ASAnu Suomalainen
Anu Suomalainen
JEJenni M Elo
Jenni M Elo
KPKirsi Pietiläinen
Kirsi Pietiläinen
AHAnna H Hakonen
Anna H Hakonen
KSKsenia Sevastianova
Ksenia Sevastianova
HTHenna Tyynismaa
Henna Tyynismaa

22 January 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BABeverley H Anderson
Beverley H Anderson
PKPaul Kasher
Paul Kasher
JMJosephine Mayer
Josephine Mayer
MSMarcin Szynkiewicz
Marcin Szynkiewicz
EJEmma M Jenkinson
Emma M Jenkinson
YCYanick J Crow
Yanick J Crow

15 April 2009 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
BBB W M van Bon
B W M van Bon
HMH C Mefford
H C Mefford
BMB Menten
B Menten
DKD A Koolen
D A Koolen
ASA J Sharp
A J Sharp
BVB B A de Vries
B B A de Vries
Background: Recurrent 15q13.3 microdeletions were recently identified with identical proximal (BP4) and distal (BP5) breakpoints and associated with mild to moderate mental retardation and epilepsy. Methods: To assess further the clinical implications of this novel 15q13.3 microdeletion syndrome, 18 new probands with a deletion were molecularly and clinically characterised. In addition, we evaluated the characteristics of a family with a more proximal deletion between BP3 and BP4. Finally, four patients with a duplication in the BP3–BP4–BP5 region were included in this study to ascertain the clinical significance of duplications in this region. Results: The 15q13.3 microdeletion in our series was associated with a highly variable intra- and inter-familial phenotype. At least 11 of the 18 deletions identified were inherited. Moreover, 7 of 10 siblings from four different families also had this deletion: one had a mild developmental delay, four had only learning problems during childhood, but functioned well in daily life as adults, whereas the other two had no learning problems at all. In contrast to previous findings, seizures were not a common feature in our series (only 2 of 17 living probands). Three patients with deletions had cardiac defects and deletion of the KLF13 gene, located in the critical region, may contribute to these abnormalities. The limited data from the single family with the more proximal BP3–BP4 deletion suggest this deletion may have little clinical significance. Patients with duplications of the BP3–BP4–BP5 region did not share a recognisable phenotype, but psychiatric disease was noted in 2 of 4 patients. Conclusions: Overall, our findings broaden the phenotypic spectrum associated with 15q13.3 deletions and suggest that, in some individuals, deletion of 15q13.3 is not sufficient to cause disease. The existence of microdeletion syndromes, associated with an unpredictable and variable phenotypic outcome, will pose the clinician with diagnostic difficulties and challenge the commonly used paradigm in the diagnostic setting that aberrations inherited from a phenotypically normal parent are usually without clinical consequences.